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ciation for Thoracic Surgerydoi:10.1016/j.jtcvs.2004.04.047Background: We comparatively evaluated the protective effect of the immunophilin
ligands cyclosporine A (INN: ciclosporin), FK506, and rapamycin on the spinal
cord in a rabbit model of transient ischemia. Both cyclosporine A and FK506 inhibit
calcineurin, whereas rapamycin does not.
Methods: Thirty-six male New Zealand White rabbits were divided into the follow-
ing 6 groups: group C, 15 minutes of spinal cord ischemia; group FK, FK506 (1
mg/kg) administered 30 minutes before ischemia; group CsA, cyclosporine A (30
mg/kg) administered 30 minutes before ischemia; group CsA-C, chronic adminis-
tration of cyclosporine A (20 mg/kg) for 9 days before ischemia; group R, rapa-
mycin (1 mg/kg) administered 30 minutes before ischemia; and group RFK,
rapamycin (1 mg/kg) administered 20 minutes before FK506 pretreatment (1 mg/
kg). Group CsA-C was added because the drug does not readily cross the blood-
brain barrier. Neurologic function was evaluated by Johnson’s 5-point scale at 8, 24,
and 48 hours after ischemia, and histopathology was assessed 48 hours after
ischemia.
Results: At 24 and 48 hours after ischemia, the Johnson score was better in groups
FK (4.0  1.1), RFK (3  1.1), and CsA-C (2.7  1.2) than in group C (0.8 
1.2). Numbers of morphologically intact anterior horn cells were higher in groups
FK (31.3 9.9), RFK (23.2 4.5), and CsA-C (18.3 6.8) than in group C (6.3
 4.3).
Conclusions: FK506 and chronic administration of cyclosporine A, but not rapa-
mycin, protect the spinal cord from transient ischemia. Although these results are
compatible with inhibition of calcineurin in the mechanism of neuroprotective
action of these drugs, other effects through different pathways cannot be excluded
before further study.
Ischemic spinal cord injury is a serious complication after operation on thethoracoabdominal aorta. A number of techniques and drugs that may reducethe ischemia-reperfusion injury of the cord have been evaluated bothclinically and experimentally, with variable success. Cyclosporine A (INN:ciclosporin) and FK506 are immunosuppressive compounds that are be-lieved to exert their action through binding to small intracellular regulatory
proteins called immunophilins (cyclophilins for cyclosporine A and FK binding
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When cyclophilin A is bound to cyclosporine A, it inhibits
the phosphatase calcineurin, and this results in the inhibition
of T-cell activation. Similarly, the immunosuppressive ef-
fect of FK506 is mediated mainly through its binding to the
12-kd FKBP (FKBP12), which also results in calcineurin
inhibition. In addition to their immunosuppressive proper-
ties, these drugs have been shown to protect brain neuronal
cells from ischemia/reperfusion injury.2,3 In the setting of
transient spinal cord ischemia, however, their neuroprotec-
tive effects have not been thoroughly evaluated, and only 2
studies were found in MEDLINE that independently studied
the effect of cyclosporine A administered after ischemia in
a rabbit model4 and the effect of FK506 administered before
ischemia in a rat model.5
We designed this study to compare the protective effect
of the immunophilin ligands cyclosporine A, FK506, and
rapamycin administered before ischemia in a rabbit model
of transient spinal cord ischemia. The protective effect of
cyclosporine A given before ischemia and that of FK506 in
a different animal model may thus be validated. The effect
of rapamycin, which also binds to FKBP12 but does not
inhibit calcineurin, was evaluated to help elucidate the role
of calcineurin inhibition.
Materials and Methods
Thirty-nine male New Zealand White rabbits weighing 2.6  3.3
kg were used in this study. The animal protocol was approved by
the Hokkaido University Animal Care and Use Committee and
was in accordance with the Guide for the Care and Use of
Laboratory Animals published by the National Institutes of Health
(publication no. 85-23; revised 1985). All experiments were per-
formed in the Research Institute of Hokkaido University School of
Medicine.
The experimental model used in this study has previously been
described.6 Briefly, the animals were anesthetized with intramus-
cular administration of ketamine hydrochloride (50 mg/kg) and
maintained at 39°C (normal value in our animals) with the aid of
a heating pad (Asahi Plate Warmer TK-43; Asahi Denshi Inc,
Osaka, Japan). The marginal ear vein was cannulated for intrave-
nous drug administration. The median ear artery was cannulated to
monitor proximal aortic blood pressure. Arterial blood pressure
and rectal temperature were continuously monitored throughout
the operation.
After intravenous administration of heparin sodium (100 IU/kg), a
4F angiographic balloon catheter (A024; Goodtec, Huntington Beach,
Calif) was introduced through the surgically isolated left femoral
artery into the abdominal aorta to 15 cm from the arteriotomy. This
distance was decided so that the tip of the catheter balloon lay just
caudal to the left renal artery. This was confirmed at the postmortem
examination of the rabbits killed for catheter placement measurements
that was performed before our previous study (n  6) and was
reconfirmed before the present study (n  3). Spinal cord ischemia
was induced by inflation of the balloon. Aortic occlusion was con-
firmed by reduction in distal aortic blood pressure, which was mea-
sured through the side hole of the balloon catheter. At the end of the
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rabbits were allowed to recover at ambient temperature and were
returned to their cages.
Experimental Protocol
The rabbits were divided into 6 groups. In the control group (group
C; n  6), rabbits had 15 minutes of spinal cord ischemia, and
vehicle was intravenously administered 30 minutes before isch-
emia. In the FK506 pretreatment group (group FK; n  6), FK506
1 mg/kg was administered 30 minutes before ischemia. In the
cyclosporine A pretreatment group (group CsA; n  7), cyclo-
sporine A 30 mg/kg was administered 30 minutes before ischemia.
One animal in this group died after surgery before neurologic
evaluation and was excluded from the analysis. In the cyclosporine
A chronic administration group (group CsA-C; n  8), cyclospor-
ine A 20 mg/kg was administered intravenously for 9 days before
operation and 30 minutes before ischemia. Two animals in this
group died during chronic drug administration before operation
and were excluded from the analysis. In the rapamycin pretreat-
ment group (group R; n  6), rapamycin 1 mg/kg was adminis-
tered 30 minutes before ischemia. In group RFK (n  6),
rapamycin 1 mg/kg was administered 20 minutes before FK506
administration, and FK506 1 mg/kg was administered 30 minutes
before ischemia. Drugs were dissolved in absolute ethanol con-
taining 400 mg of polyoxyl 60 hydrogenated caster oil (1 mL/mL),
and the same vehicle was administered in group C.
Neurologic Assessment
Neurologic function was evaluated at 8, 24, and 48 hours after the
operation. Animals were graded on a 5-point scale according to the
method of Johnson and associates7: 0, hind-limb paralysis; 1,
severe paraparesis; 2, functional movement, no hop; 3, ataxia,
disconjugate hop; 4, minimal ataxia; 5, normal function. One
member of the research team without knowledge of the treatment
graded neurologic function.
Histologic Assessment
Immediately after neurologic testing, the animals were killed under
deep anesthesia with sodium pentobarbital (50 mg/kg intrave-
nously), and the spinal cords were quickly removed. They were
fixed by immersion in 2% paraform/aldehyde/15% picric acid in
0.1 mol/L phosphate buffer and embedded in paraffin. Serial
transverse sections (5 m) were obtained at the level of L3-4. They
were stained with hematoxylin and eosin for histopathologic ob-
servations. Numbers of morphologically intact anterior horn cells
were calculated in each group and were compared.
Statistical Analysis
Data are expressed as mean  SD. The Mann-Whitney U test was
used for nonparametric comparison of the Johnson score between
2 groups. The Kruskal-Wallis test was used for nonparametric
comparison of the temporal change in the Johnson score.
Results
In all groups, the mean distal aortic pressure decreased to
less than 20 mm Hg after balloon inflation. The rectal
temperature decreased by approximately 0.5°C during bal-
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15 minutes after reperfusion. No significant difference was
found in these parameters among the groups at any time
point.
Neurologic Outcome
The average Johnson score after 8 hours was 2.0  1.1 in
group C, 3.7  0.8 in group FK, 1.7  1.0 in group CsA,
3.2  0.8 in group CsA-C, 1.2  1.3 in group R, and 3.7 
0.8 in group RFK (Figure 1). After 24 hours, the score
was 0.8  1.2 in group C, 4.0  1.1 in group FK, 1.5  0.8
in group CsA, 2.7 1.2 in group CsA-C, 0.7 0.8 in group
R, and 3.0  1.1 in group RFK. After 48 hours, the score
was 0.7  0.8 in group C, 4.0  1.1 in group FK, 1.5  0.8
in group CsA, 2.7 1.2 in group CsA-C, 0.7 0.8 in group
R, and 3.0  1.1 in group RFK. The differences between
groups at 8 hours were not statistically significant. At 24 and
48 hours, the motor function of group FK and group RFK
was significantly better than that in groups C, CsA, and R.
The motor function of group CsA-C was also significantly
better than that in groups C and R at 24 and 48 hours. The
difference between group CsA and CsA-C (P  .08) and
between group FK and CsA-C (P  .07) at 24 and 48 hours
was not statistically significant.
Histopathologic Outcome
In groups FK, CsA-C, and RFK, many large motor neu-
rons were seen in the anterior horn, in which nuclear struc-
tures were retained, nuclei were integrated, and membranes
were smooth (Figure 2). In other groups, however, the gray
matter had vacuums in places that should be the trace of
dead neurons; remaining large motor neurons showed
shrinkage, their nuclei showed chromatic agglutination and
nucleolar disintegration, and their shape underwent distor-
tion similar to that of the whole cell. The density of glial
cells in the gray matter showed the same change.
The average numbers of morphologically intact anterior
horn cells in each group are summarized in Figure 3: 6.3 
4.3 in group C, 31.3  9.9 in group FK, 10.3  10.7 in
group CsA, 18.3  6.8 in group CsA-C, 12.5  10.4 in
group R, and 23.2  4.5 in group RFK. The differences
between group C and groups FK, CsA-C, and RFK and
those between group FK and groups C, R, and CsA were
statistically significant (group C vs group FK, P  .0002;
group C vs group CsA-C, P  .0044; group C vs group
RFK, P .0001; group FK vs group C, P .0002; group
FK vs group R, P  .0095; group FK vs group CsA, P 
.0054).
Discussion
The results of this study not only confirmed the neuropro-
tective effect of FK506 against transient spinal cord isch-
emia in a different animal model, but also showed for the
The Journal of Thoracifirst time that rapamycin, which binds to FKBP12 without
calcineurin inhibition, does not have a protective effect in
the same model. The protective effect of cyclosporine A
could be shown by chronic administration of 20 mg/kg, but
we failed to show it by single preischemic administration of
30 mg/kg—the dose that was reported effective in the
previous study by postischemic administration.4
The result that FK506, but not rapamycin, showed a
Figure 1. Neurologic outcome graded by Johnson’s score. Group
C, Control group; group FK, FK506 pretreatment group; group CsA,
cyclosporine A pretreatment group; group CsA-C, cyclosporine A
chronic administration group; group R, rapamycin pretreatment
group; group RFK, rapamycin administration before FK506 pre-
treatment group. *Statistically significant difference compared
with group C (24 hours, FK P  .007, CsA-C P  .024, RFK P 
.008; 48 hours, FK P  .007, CsA-C P  .024, RFK P  .008).protective effect is consistent with previous reports.3,8
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animal models of transient cerebral ischemia.9-11 Lang-
Figure 2. Light microscopy of spinal cord tissue staine
(original magnification, 100); b, FK506 pretreatment gro
magnification, 100); d, control group (original magnificat
neurons were seen in the anterior horn, in which nuclear
had vacuums in places, and remaining large motor neur
Figure 3. Number of anterior horn cells in each group. Group C, Control
group; group FK, FK506 pretreatment group; group CsA, cyclosporine A
pretreatment group; group CsA-C, cyclosporine A chronic administration
group; group R, rapamycin pretreatment group; group RFK, rapamycin
administration before FK506 pretreatment group. *Statistically signifi-
cant difference compared with group C (FK P .0002; CsA-C P .0044;
RFK P < .0001).Lazdunski and colleagues5 have also reported a protective
126 The Journal of Thoracic and Cardiovascular Surgery ● Janueffect of FK506 1 mg/kg in the rat model of transient spinal
cord ischemia. The dose of rapamycin was also set at 1
mg/kg because it has almost the same structure and molec-
ular weight as FK506. Sharkey and Butcher3 have reported
in a rat model of brain ischemia that rapamycin 1 mg/kg did
not protect the brain. Although rapamycin binds with high
affinity to FKBP12 at the same site as FK506, rapamycin-
bound FKBP12 interacts not with calcineurin, but also with
a different target called (Rapamycin and FKBP-12 Target)
(RAFT),1 and this may explain the different behavior of the
2 drugs.
The reason that single preischemic administration of
cyclosporine A 30 mg/kg was not effective may be ex-
plained by the poor blood-brain barrier permeability of the
drug,12 because a protective effect could be shown by
chronic administration of 20 mg/kg. A similar dosage
schedule has been reported effective to overcome the prob-
lem of blood-brain barrier permeability in an in vivo model
of brain ischemia.2 Although a protective effect of postisch-
emic single administration of cyclosporine A 30 mg/kg was
shown in the previous study in a rabbit model of spinal cord
th hematoxylin and eosin. a, FK506 pretreatment group
riginal magnification, 400 ); c, control group (original
00). In the FK506 pretreatment group, many large motor
tures were retained. In the control group, the gray matter
howed shrinkage and chromatic agglutination.d wi
up (o
ion, 4
strucischemia,4 the discrepancy may be explained by the differ-
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brain barrier may be damaged after ischemia, cyclosporine
A can more readily be distributed to the cord by postisch-
emic administration.
Despite many studies, the mechanisms of the neuropro-
tective action of cyclosporine A and FK506 remain contro-
versial. Many studies have suggested that neuronal cal-
cineurin inhibition—for example, by preventing neuronal
nitric oxide synthase activation13 or by preventing activa-
tion of the proapoptotic protein BAD14—mediates neuro-
protective action. In addition, anti-inflammatory actions of
these drugs, such as suppression of the proinflammatory
cytokines through their effects on leukocyte calcineurin,
may also be involved. The results of this study—that FK506
and chronic administration of cyclosporine A, but not rapa-
mycin, had neuroprotective effects—agree with the involve-
ment of these mechanisms.
Several mechanisms other than calcineurin inhibition
have been reported which may also explain the neuropro-
tective action of FK506 and cyclosporine. Cyclosporine A
has been reported to exert its neuroprotective effect not only
as a calcineurin inhibitor, but also as a blocker of mitochon-
drial permeability transition pores.15 The latter action is
mediated through the mitochondrial matrix-specific cyclo-
philin D and is not observed for FK506.15 FK506 has been
reported to have an antiapoptotic action that is not mediated
through calcineurin inhibition,10,11,16 and involvement of
neuronzal calcineurin inhibition in the mechanism of neu-
roprotective action was not supported in several studies.16,17
The result that FK506 tended to be more effective than
chronic administration of cyclosporine A may suggest in-
volvement of such pathways. However, it may also be
explained by the differences in drug distribution to the
spinal cord.
FK506 also has a neuroregenerative effect, as evidenced
by the promotion of neurite outgrowth, in addition to its
neuroprotective effects.18 Recent studies have suggested
that FKBP52, a component of the steroid receptor complex,
but not FKBP12, is necessary for this effect.19 Promotion of
neurite outgrowth, however, is observed 2 to 6 days after
FK506 treatment, and the neuroprotective effect is shown
just after reperfusion. In addition, rapamycin, which does
not have the neuroprotective effect, has also been reported
to have a neuroregenerative effect.18 Therefore, the neuro-
regenerative effect does not seem to explain the neuropro-
tective effect seen in this study.
Our result that rapamycin 1 mg/kg administered before
FK506 did not completely inhibit the neuroprotective effect of
FK506 1 mg/kg is confusing. Because rapamycin competes the
binding site to FKBP12 with FK506, it should have inhibited
the effect of FK506 if calcineurin inhibition were the mecha-
nism of its action. This confusing result may be explained by
an insufficient dose of rapamycin relative to that of FK506.
The Journal of ThoraciSharkey and Butcher3 have reported in a rat model of brain
ischemia that rapamycin 1 mg/kg blocked the protective effect
of FK506 0.1 mg/kg. Therefore, further studies with different
doses of the drugs will be required in this aspect, and the role
of calcineurin inhibition in their mechanism remains specula-
tive. Other effects through different pathways cannot be ex-
cluded before further study.
Clinically, FK506 is much more attractive than cyclo-
sporine A in that a single administration of 1 mg/kg has a
strong neuroprotective effect. Actually, the administration
of cyclosporine A 20 mg/kg for 9 days was lethal in 2 of 8
animals in this study and is not practical. Recently it has
been reported that a lower dose of FK506 is also effective
for protecting the brain from ischemia.8,17 Therefore, fur-
ther studies with smaller doses will be required to determine
the optimal dosage schedule of FK506.
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